Prostate Cell News Volume 7.05 | Feb 12 2016

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide through the Androgen Receptor V7
Researchers aimed to elucidate the kinome in castration-resistant prostate cancer as well as the role of key molecules. [J Natl Cancer Inst] Abstract

Integration of Lipidomics and Transcriptomics Unravels Aberrant Lipid Metabolism and Defines Cholesteryl Oleate as Potential Biomarker of Prostate Cancer
Scientists performed lipidomics and transcriptomics in paired prostate cancer tumor and adjacent nontumor tissues, followed by external validation of biomarker candidates. [Sci Rep] Full Article

Role of Protease-Activated Receptor 2 in the Development of Lower Urinary Tract Dysfunction
Researchers reported that the mast cell-tryptase-protease-activated receptor 2 (PAR2) axis plays a critical role in the development of chronic pain in experimental autoimmune prostatitis, a mouse model of chronic prostatitis/chronic pelvic pain syndrome. They therefore examined whether PAR2 activation mediates lower urinary tract dysfunction. [J Urol] Abstract

Prostate Cancer-Derived Cathelicidin-Related Antimicrobial Peptide Facilitates Macrophage Differentiation and Polarization of Immature Myeloid Progenitors to Protumorigenic Macrophages
To investigate protumorigenic role(s) of cathelicidin-related antimicrobial peptide (CRAMP), a murine orthologue of leucin leucin 37, investigators compared tumor growth kinetics between mouse prostate cancer cell lines with and without CRAMP expression in immunocompetent mice. [Prostate] Abstract

CLINICAL RESEARCH

The Use of a Gas Chromatography-Sensor System Combined With Advanced Statistical Methods, Towards the Diagnosis of Urological Malignancies
Researchers proposed a gas chromatography-sensor algorithm system for classifying urine samples from patients with urological symptoms. The pilot study included 155 men presenting to urology clinics, 58 were diagnosed with prostate cancer, 24 with bladder cancer and 73 with hematuria and or poor stream, without cancer. [J Breath Res] Abstract | Press Release

The ERSPC Risk Calculators Significantly Outperform the PCPT 2.0 in the Prediction of Prostate Cancer; a Multi-Institutional Study
To analyze the performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) and two iterations of the European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC), one of which incorporates prostate volume and another which incorporates prostate volume and the Prostate Health Index in a referral population. [BJU Int] Abstract

The Prognostic Impact of Serum Testosterone during Androgen-Deprivation Therapy in Patients with Metastatic Prostate Cancer and the SRD5A2 Polymorphism
Scientists investigated the relationship between androgen-deprivation therapy (ADT) serum testosterone levels or body mass index and the prognosis among men treated with primary ADT for metastatic prostate cancer. [Prostate Cancer Prostatic Dis] Abstract

Stratification of Aggressive Prostate Cancer from Indolent Disease-Prospective Controlled Trial Utilizing Expression of 11 Genes in Apparently Benign Tissue
Investigators evaluated the diagnostic power of molecular markers in men with a clinical suspicion of prostate cancer using apparently benign areas as targeted by magnetic resonance imaging. [Urol Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

PDS Biotechnology Signs Agreement with National Cancer Institute
PDS Biotechnology announced that the company has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the CRADA, PDS and NCI aim to co-develop several immunotherapies through Phase II clinical trials utilizing combinations of Versamune^® with NCI- and PDS-sourced tumor-related proteins or their fragments recognized by the immune system in prostate, breast, and HPV-related cancers. [PDS Biotechnology Corporation] Press Release

AUA Announces 2016 Annual Award Winners
The American Urological Association (AUA) announced the list of 2016 award recipients who will be honored at the Association’s upcoming Annual Meeting. These physician researchers and educators are being honored for their contributions to the field of medicine, the specialty of urology and the AUA. [The American Urological Association] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Fellowship – Cancer Epigenomics (Princess Margaret Cancer Centre)

NEW Postdoctoral Fellowship – Prostate Cancer Biology (Medical University of South Carolina )

Postdoctoral Fellowship – Prostate Cancer and Cancer Metabolism (Cleveland Clinic)

Post-Doc Fellowship – Metastasis of Cancer (University of Arizona Cancer Center)

Post-Doc Fellowship – Molecular Imaging for Prostate Cancer (Case Western Reserve University)

Post-Doc Fellowship/Staff Scientist – Prostate Cancer Epidemiology (Memorial Sloan Kettering Cancer Center)

Faculty Position – Urology Research (Mayo Clinic)

Post-Doc Fellowship – Cancer Stem Cell Biology (Weill Cornell Medical College)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.